Novavax reported Q2 earnings of $0.58 per share, beating the analyst consensus estimate of $(1.24) by 146.77%. This is a 108.88% increase over losses of $(6.53) per share from the same period last year. The company also reported quarterly sales of $424.43 million, beating the analyst consensus estimate of $257.62 million by 64.75%. This is a 128.28% increase over sales of $185.93 million the same period last year.